Somatic hypermutation (SHM) is a regulated process that introduces unusually frequent mutations into the DNA encoding the variable regions of antibodies in activated B cells. It generates related cells with different antigen-binding properties, providing variation on which selection acts during affinity maturation. A central mechanism of adaptive immunity, SHM depends on activation-induced cytidine deaminase and the mutagenic processing of DNA lesions. Mutation itself does not necessarily improve antibody binding; improvement emerges through subsequent selection. (pubmed.ncbi.nlm.nih.gov)
Biological setting and targets
In mammals, SHM is strongly associated with the germinal centers that develop in secondary lymphoid organs during immune responses. Germinal-center B cells undergo repeated cycles of proliferation, mutation, and selection. Their surface immunoglobulins provide a means of testing the binding properties of newly generated variants against antigen. Descendants of a single responding B cell can therefore acquire distinct antibody sequences while remaining members of the same clonal lineage. (pmc.ncbi.nlm.nih.gov)
The principal antibody targets are the rearranged variable-region genes of immunoglobulin heavy and light chains, together with nearby transcribed sequences. SHM predominantly produces single-base substitutions, although insertions and deletions also occur. Frequently cited mutation rates are approximately 10⁻⁴–10⁻³ substitutions per base per cell generation, substantially above ordinary background mutation rates. These estimates describe targeted regions under particular experimental conditions rather than a uniform rate across the genome. (pmc.ncbi.nlm.nih.gov)
“Somatic” distinguishes these changes from inherited germline variation. They diversify the responding B-cell lineage rather than altering the inherited antibody-gene repertoire of the organism’s offspring. Within the variable region, substitutions may change amino acids involved in antigen recognition or affect the structural framework supporting the binding site. (pmc.ncbi.nlm.nih.gov)
Initiation by cytidine deamination
The initiating enzyme is activation-induced cytidine deaminase (AID), encoded by AICDA. Experiments reported in 2000 established that AID-deficient mice fail to carry out normal SHM and immunoglobulin class switching. Subsequent biochemical experiments demonstrated that AID converts cytosine to uracil in single-stranded DNA, establishing a direct route from its enzymatic activity to antibody-gene diversification. (pubmed.ncbi.nlm.nih.gov)
AID requires accessible single-stranded DNA rather than an intact double helix. Transcription helps create suitable substrates, and antibody hypermutation is concentrated within a limited region downstream of transcriptional control elements. Deamination converts an ordinary cytosine–guanine pair into a uracil–guanine mismatch. This lesion is the starting point for several alternative processing pathways, not a completed mutation in every case. (pubmed.ncbi.nlm.nih.gov)
Mutagenic processing of DNA lesions
SHM repurposes components of DNA repair, allowing lesions to generate sequence diversity rather than always restoring the original sequence. The outcome depends partly on how the uracil–guanine mismatch is handled:
- Replication across uracil: During DNA replication, uracil can template adenine, fixing a cytosine-to-thymine transition or its complementary guanine-to-adenine change.
- Uracil removal: Uracil-DNA glycosylase (UNG), associated with base excision repair, removes uracil and leaves an abasic site. Error-prone copying or processing of that site can generate additional substitutions at the original cytosine–guanine pair.
- Mismatch-directed processing: The MSH2–MSH6 complex of DNA mismatch repair recognizes the mismatch. Excision and mutagenic resynthesis can extend sequence changes to neighboring adenine–thymine pairs. (pmc.ncbi.nlm.nih.gov)
DNA polymerase η is particularly important for mutations at adenine–thymine pairs. Biochemical experiments demonstrated physical and functional interactions between this polymerase and MSH2–MSH6. Studies of human B-cell repertoires with defects in UNG or mismatch-repair proteins likewise reveal characteristic changes in mutation spectra. These pathways interact; they are not completely independent routes with identical contributions in every setting. (pubmed.ncbi.nlm.nih.gov)
Sequence bias and affinity selection
SHM is stochastic but not sequence-uniform. Mutations preferentially occur at hotspot motifs such as WRCY and its reverse complement RGYW, where W denotes A or T, R denotes A or G, and Y denotes C or T. Local nucleotide context and the enzymes processing lesions influence which substitutions arise. Hotspots create mutational biases, but they do not instruct the system to produce a particular beneficial antibody. (pmc.ncbi.nlm.nih.gov)
Selection is a separate cellular process. In the germinal-center light zone, B cells capture antigen and present derived peptides through major histocompatibility complex class II molecules. T follicular helper cells, a specialized T-cell population, provide signals that favor expansion of selected B cells. Experimental manipulation of antigen presentation shows that greater access to T-cell help can increase both subsequent cell division and accumulated hypermutation. (pubmed.ncbi.nlm.nih.gov)
Mutation and selection therefore form an iterative process: variants arise, their binding and presentation properties affect competitive success, and selected cells undergo further expansion. This process can also produce antibody-secreting plasma cells and memory B cells, although these output populations need not represent identical selections of the evolving repertoire. (pmc.ncbi.nlm.nih.gov)
Relationship to other diversification mechanisms
SHM differs from V(D)J recombination, which assembles variable-region gene segments during early B-cell development. SHM instead modifies already rearranged antibody sequences. It also differs from class-switch recombination, which changes the heavy-chain constant region and thereby antibody effector properties. SHM and class switching both require AID, but they act on different regions and produce different genetic outcomes. (pubmed.ncbi.nlm.nih.gov)
Experimental and disease relevance
DNA sequencing allows researchers to compare mutated immunoglobulin sequences with inferred germline sequences, examine substitution patterns, and reconstruct clonal relationships. Human genetic defects provide complementary evidence: AID deficiency disrupts SHM and class switching, while defects in lesion-processing proteins can alter which mutations are produced. (pmc.ncbi.nlm.nih.gov)
AID activity is not absolutely restricted to immunoglobulin genes. Genome-wide experimental mapping has identified non-immunoglobulin targets in germinal-center B cells. Such off-target damage helps explain why the targeting and processing of AID lesions are relevant to the genetic abnormalities associated with B-cell lymphomas. Normal antibody diversification and potentially harmful mutagenesis thus share an initiating enzymatic activity, although their biological outcomes differ. (rupress.org)